| Gene symbol | PMEL | Synonyms | D12S53E, HMB-45, HMB45, ME20, ME20-M, ME20M, P1, P100, PMEL17, SI, SIL, SILV, gp100 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12q13.2 | dbXrefs | |
| Description | premelanosome protein | ||||
| GTO ID | GTC1701 |
| Trial ID | NCT03070392 |
| Disease | Uveal Melanoma |
| Altered gene | gp100 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | gp100 TCR-T cells |
| HLA | HLA-A*02:01 |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma |
| Year | 2017 |
| Country | United States |
| Company sponsor | Immunocore Ltd |
| Other ID(s) | IMCgp100-202 |
| Cohort 1 | |||||||||||
|
|||||||||||